Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: The jury is still out

Arthritis Care and Research

Volumn 59, Issue 8, 2008, Pages 1082-1089

  Allaire, Saralynn ^a,c   Wolfe, Frederick ^b   Niu, Jingbo ^a   Zhang, Yuqing ^a   Zhang, Bin ^a   LaValley, Michael ^a  

^a BOSTON UNIVERSITY   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c Clinical Epidemiology Research and Training Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SCREENING; EMPLOYMENT; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; WORK DISABILITY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DISABILITY EVALUATION; EMPLOYMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SICK LEAVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49549117318     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23923     Document Type: Article

References (33)

1. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996;44:47-51.
2. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
3. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528-34.
4. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 2006;45:325-31.
5. Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden. Scand J Rheumatol 2007;36:179-83.
6. Verstappen SM, Jacobs JW, Hyrich KL. Effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2126-8.
7. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9.
8. Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-8.
9. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004;43 Suppl 3:iii17-23.
10. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
11. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54.
12. Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 2006;33:665-70.
13. Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, et al. Short-term impact of adalimumab on productivity outcomes in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2007;56 Suppl 9:S89.
14. Klein-Geltink JE, Rochon PA, Dyer S, Laxer M, Anderson GM. Readers should systematically assess methods used to identify, measure and analyze confounding in observational cohort studies. J Clin Epidemiol 2007;60:766-72.
15. US Census Bureau. Basic Monthly Survey CPS Questionnaire. 1997. URL: http://www.bls.census.gov/cps/bqestair.htm.
16. Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, et al, on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys [review]. Arthritis Rheum 2004;51:488-97.
17. Allaire SH. Update on work disability in rheumatic diseases. Curr Opin Rheumatol 2001;13:93-8.
18. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
19. Lacaille D, Sheps S, Spinelli JJ, Chalmers A, Esdaile JM. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum 2004;51:843-52.
20. Reisine S, McQuillan J, Fifield J. Predictors of work disability in rheumatoid arthritis patients: a five-year followup. Arthritis Rheum 1995;38:1630-7.
21. Cook EF, Goldman L. Empiric comparison of multivariate analytic techniques: advantages and disadvantages of recursive partitioning analysis [published erratum appears in J Chronic Dis 1986;39:157]. J Chronic Dis 1984;37:721-31.
22. Bloch DA, Moses LE, Michel BA. Statistical approaches to classification: methods for developing classification and other criteria rules. Arthritis Rheum 1990;33:1137-44.
23. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Monterey (CA): Wadsworth; 1984.
24. Breiman L. Random forests. Mach Learn 2001;45:5-32.
25. Breiman L. Manual on setting up, using, and understanding random forests V3.1. 2002. URL: http://oz.berkeley.edu/users/breiman/Using_random_forests_V3.1. pdf.
26. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211-7.
27. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis: development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007;34:481-7.
28. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
29. Wakefield RJ, Freeston JE, Hensor EM, Bryer D, Quinn MA, Emery P. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. Arthritis Rheum 2007;57:1564-67.
30. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.
31. Felson DT, Zhang B, Siegel JN. Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable. Ann Rheum Dis 2008;67:580-3.
32. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007;57:935-42.
33. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6.